Compare AU
Compare CFLO vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the BetaShares Global Cash Flow Kings ETF (CFLO) and the BetaShares Global Healthcare Currency Hedged ETF (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
CFLO | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 11 | 61 |
Median incremental investment | $1,023.46 | $920.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $3,036.96 | $1,976.53 |
Average age group | > 35 | 26 - 35 |
Key Summary
CFLO | DRUG | |
|---|---|---|
Strategy | CFLO.AX was created on 2023-11-14 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The investment objective of the Fund is to provide an investment return that aims to track the performance of the Solactive Global exAustralia Cash Flow Kings Index. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | BERKSHIRE HATHAWAY INC (4.48 %) ALPHABET INC (4.21 %) VISA INC (3.87 %) | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) |
Top 3 industries | Other (30.37 %) Information Technology (26.44 %) Financials (12.25 %) | Other (75.92 %) Communication Services (33.53 %) Health Care (23.94 %) |
Top 3 countries | United States (73.41 %) Japan (8.36 %) Switzerland (3.49 %) | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) |
Management fee | 0.4 % | 0.57 % |
Key Summary
CFLO | DRUG | |
|---|---|---|
Issuer | BetaShares | BetaShares |
Tracking index | Solactive Global ex-Australia Cash Flow Kings Index - AUD - Benchmark TR Net | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.4 % | 0.57 % |
Price | $17.76 | $8.27 |
Size | $33.764 million | $195.730 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 0.36 % | 1.89 % |
Market | ASX | ASX |
First listed date | 15/11/2023 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
CFLO | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 11 | 61 |
Median incremental investment | $1,023.46 | $920.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $3,036.96 | $1,976.53 |
Average age group | > 35 | 26 - 35 |
Pros and Cons
CFLO | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
CFLO | DRUG |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Lower distribution yield | Higher distribution yield |